Latest News for: acutance

Edit

Around 40 patients in IMH Covid-19 cluster transferred to acute hospitals

Straits Times 04 Nov 2021
SINGAPORE - Patients at the Institute of Mental Health (IMH) with more serious Covid-19 symptoms will be transferred to acute hospitals if required, IMH told The Straits Times on Thursday (Nov 4). And so far, about 40 have been transferred ... IMH added ... ....
Edit

ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza� and Venclexta� in Relapsed/Refractory Acute Myeloid ...

Business Wire 04 Nov 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza� and Venclexta� in Relapsed/Refractory Acute Myeloid Leukemia at ASH ... .
Edit

DSS Expands American Medical REIT with Acquisition of Three Established Acute Care Hospitals in Texas ...

Nasdaq Globe Newswire 04 Nov 2021
... LifeCare Hospitals (together with its affiliates, “LifeCare Hospitals”), a specialty hospital operator with a focus on long-term acute and critical care.
Edit

DSS Expands American Medical REIT with Acquisition of Three Established Acute Care Hospitals in Texas and Pennsylvania (Document Security Systems Inc)

Public Technologies 04 Nov 2021
) ... The Hospitals are currently tenanted and operated by LifeCare Hospitals (together with its affiliates, "LifeCare Hospitals"), a specialty hospital operator with a focus on long-term acute and critical care ... Disclaimer ... (noodl. 59371248) .
Edit

Few Acute Care Hospitals Escaped Readmissions Penalties

The Daily Times 04 Nov 2021
Preventable rehospitalization of the nation’s older adults has proved a persistent health and financial challenge for the U.S., costing Medicare hundreds of millions of dollars each year ... .
Edit

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Business Wire 04 Nov 2021
FR0014005OJ5 – ALACT), a clinical stage biotechnology company involved in the acute phase of ...
Edit

Acute Respiratory Distress Syndrome (ARDS) Market Share, Size, Key Players, Trends, Competitive & Forecasts To 2027

MENA FN 04 Nov 2021
(MENAFN - EIN Presswire) Reports And Data Rise in the chronic diseases and increase in the air pollution & air quality NEW YORK, NY, UNITED STATES, November 4, 2021 /EINPresswire.com / -- The ... .
Edit

Health Minister opens new £115m Acute Services block at Ulster Hospital

Belfast Telegraph 04 Nov 2021
The Health Minister Robin Swann has officially opened a new £115m Acute Services Block at the Ulster Hospital ... Using surgical scissors, Health Minister Robin Swann officially opens the new £115m Acute Services Block at the Ulster Hospital ... “This Acute Services Block will enable ...
Edit

Minister Swann Opens £115m Ulster Hospital’s New Acute Services Block (Department of Health - Northern Ireland Government)

Public Technologies 04 Nov 2021
Health Minister Robin Swann has officially opened the initial phase of the new £115million Acute Services Block (ASB) at Ulster Hospital, Dundonald ... "This Acute Services Block will enable staff to continue to deliver a high quality of care to acutely unwell patients, in a superior work environment.
Edit

Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

PR Newswire 04 Nov 2021
Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML) ... the DIAMOND-01 trial (CLI24-001; clinicaltrials.gov identifier NCT03008187) for the treatment of relapsed/refractory Acute Myeloid Leukemia.
Edit

Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia (A Menarini Industrie Farmaceutiche Riunite Srl)

Public Technologies 04 Nov 2021
Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML) ... the DIAMOND-01 trial (CLI24-001; clinicaltrials.gov identifier NCT03008187) for the treatment of relapsed/refractory Acute Myeloid Leukemia.
Edit

Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy

PR Newswire 04 Nov 2021
Our lead product candidate, I-131 apamistamab (Iomab-B) has been studied in several hundred patients including in the recently fully enrolled, 150-patient, pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.
Edit

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

The Baytown Sun 04 Nov 2021
AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that AFM28, its novel Innate Cell Engager (ICE®), is designed to treat patients with Acute Myeloid Leukemia (AML) and other CD123+ myeloid malignancies, such as high-risk myelodysplastic syndrome (MDS).
×